Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of TPO-RA Transformation in ITP
NCT04890041Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2021
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial in primary immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Treatment response at 6 weeks. Started May 2021; status: recruiting.
02
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04890041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04890041.